Evelo Biosciences
2014
FOUNDED
PUBLIC
STATUS
51-60
EMPLOYEES
EVLO
STOCK SYMBOL
1
INVESTMENTS
$11.39
SHARE PRICE
(As of Friday Closing)
Description
Developer of monoclonal microbials created to to improve the lives of patients with serious diseases through the development of a broadly applicable new modality of medicines. The company's monoclonal microbials act through the gut to modulate biology that impacts many diseases and leverages the ability of specific strains of bacteria, to potently activate the immune system against tumors and down-regulate the immune system providing the treatment of autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer
Website
Formerly Known As
Evelo Therapeutics, VL28
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 620 Memorial Drive
- Suite 200 West
- Cambridge, MA 02139
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Evelo Biosciences’s full profile, request a free trial.
Evelo Biosciences Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $7.29 - $16.26 | $328M | $10.32 | $2.59 | 38.8K | 31.8M |
Evelo Biosciences Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|
| Enterprise Value | 222,464 | ||
| Revenue | 0 | ||
| EBITDA | (48,840) | (26,998) | (12,550) |
| Net Income | (49,646) | (28,047) | (13,332) |
| Total Assets | 175,606 | 43,788 | 18,570 |
| Total Debt | 14,155 | 9,966 | 9,931 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Evelo Biosciences Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Evelo Biosciences‘s full profile, request access.
Request full access to PitchBookEvelo Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Evelo Biosciences‘s full profile, request access.
Request full access to PitchBookEvelo Biosciences Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 00000000000 | 12-Jul-2016 | 000000000000000000 | Biotechnology | 0000000000 0000 00.0 |
Evelo Biosciences Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Evelo Biosciences‘s full profile, request access.
Request full access to PitchBookEvelo Biosciences Executive Team (13)
2 Former Executives
You’re viewing 5 of 13 executives. Get the full list »Evelo Biosciences Board Members (8)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Balkrishan Gill Ph.D | Evelo Biosciences | Chief Executive Officer, President & Board Member | 000 0000 | |
| David Berry Ph.D | Flagship Pioneering | Board Member & Co-Founder | 000 0000 | |
| David Epstein | Flagship Pioneering | Board Member | 000 0000 | |
| David Perry | Self | Director | 000 0000 | |
| Mark Pruzanski MD | Self | Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 8 board members. Get the full list »